GM - LATEST ISSUE - January 2012
Articles in GM:
National Audit of Dementia
The first full report of the National Audit of
Dementia has identified a need for significant improvements in
hospital ward environments, staff training and the overall approach
to care delivery for patients with dementia.
New drug for C.
difficile
The European Commission has granted a marketing
authorisation for fidaxomicin (DIFICLIR™) tablets for the treatment
of adults with Clostridium difficile infections (CDI), also known as
C. difficile-associated diarrhoea (CDAD), in the European
Union.
Wales patients to receive
Dupuytren's contracture treatment
NHS patients in Wales will now have access to the
first licensed injectable treatment option for Dupuytren's
contracture, which has been recommend for restricted use by All Wales
Medicine Strategy Group (AWMSG).
Collagenase clostridium histolyticum (Xiapex®) was
launched in the UK in April 2011, to treat Dupuytren's
contracture in adult patients with a palpable cord. Collagenase
clostridium histolyticum offers an alternative treatment option to
surgery for Dupuytren's contracture.
New AF registry
The first patient has been enrolled into the
PREvention oF thromboembolic events - European Registry in Atrial
Fibrillation (PREFER in AF). Taking a comprehensive approach to the
patient registry, PREFER in AF will gather data on the full spectrum
of AF patients including those with valvular and non valvular forms
of the condition.
NICE criticised for
prostate drug
The Prostate Cancer Charity has criticised NICE
for not recommending the newly licensed chemotherapy drug cabazitaxel
as a treatment for men with advanced prostate cancer despite evidence
the drug significantly extends the lives of men in the advanced
stages of the disease.
A new vision for old
age
In a new study from the Economist Intelligence
Unit on healthcare provision for an ageing population, supported by
Pfizer, the overwhelming majority of health professionals surveyed
(80%) express their concern about how they will be treated when they
grow old. They are sceptical that current policies to address
demographic shift caused by an ageing population are comprehensive,
realistic or sufficiently funded to address future demand.
GM
Bulletin
For the latest articles, news on research, policy, and practice and
information, subscribe to our monthly e-alert GM Bulletin by emailing
GMnews@oceanmedia.co.uk
Want to know more about diabetes?
Glycosmedia was launched in June 2008, and is
dedicated to bringing a free, non-promotional, editorially
independent e-mail newsletter to a global audience about
developments and news in diabetes, and is primarily aimed at health
professionals. It is supported by educational
grants from Abbott, Bayer, Lilly and Novo Nordisk,
andalso has an active "Featured
Events" section where organisations can advertise their
conferences and events. There is also a section for advertising
products, journals and publications.
Each week Glycosmedia is sent out by email to
1,400 healthcare professionals. The free subscription page can be
found here
http://www.glycosmedia.com/subscribe.htm